2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1035

Different Cartilage-Bone Unit in Patients with Primary Osteoarthritis and Secondary Osteoarthritis Caused By Rheumatoid Arthritis
Abstract Number: 1036

Effects of Three Potential Anabolic Disease-Modifying Osteoarthritis Drugs – Sprifermin, Insulin-like Growth Factor 1 and Bone Morphogenetic Protein 7 – on Matrix Production and the Phenotype of Articular Chondrocytes
Abstract Number: 1037

Develop an in Vitro Model to Test the Different Behavior of mtDNA in OA and Healthy Patients, Based on Mitochondrial Activity and Metabolic Response
Abstract Number: 1038

Tenofovir, a Nucleoside Analog Reverse Transcriptase Inhibitor for Treatment of HIV, Promotes Osteoclast Differentiation and Decreases Osteoblast Formation By a Mechanism Depending on ATP Release and Adenosine
Abstract Number: 1039

Tenofovir Induces Osteopenia and Dipyridamole, an Inhibitor of the Ent-1 Nucleoside Transporter, Reverses the Osteopenic Effect of Tenofovir In Vivo
Abstract Number: 1040

The Potential Role of Choline Kinase Alpha in Osteoarthritis
Abstract Number: 1041

The Anti-Adamts-5 Nanobody®, M6495, Protects Against Cartilage Breakdown in Cartilage and Synovial Joint Tissue Explant Models
Abstract Number: 1042

Development of a Neo-Epitope Specific Assay for Serological Assessment of Type X Collagen Degradation and Its Potential Diagnostic Value for Knee Osteoarthritis
Abstract Number: 1043

Computational Analysis of Potential Self-Antigens in Osteoarthritis
Abstract Number: 1044

Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model
Abstract Number: 1045

The Coll2-1 Peptide of Collagen Type II: A New Actor of Synovitis in Osteoarthritis
Abstract Number: 1046

Distinct Balance of TNF-α/IL-10 in Circulating and Infiltrating CD163+ Macrophages between Rapidly and Slowly Progressive Symptomatic Knee Osteoarthritis
Abstract Number: 1047

Signaling at Adenosine A2A Receptor (A2aR) in Osteoblasts; Crosstalk with Wnt/ β-Catenin Signaling Pathway
Abstract Number: 1048

Identification of Novel Molecules with Senolytic and Autophagy Activity As Osteoarthritis Therapeutics
Abstract Number: 1049

Optical Biomarkers for the Early Diagnosis of Osteoarthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].